This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Inhibiting a metabolic pathway provides new approach to Epstein-Barr virus and resulting diseases

Epstein-Barr virus (EBV)
This electron microscopic image of two Epstein Barr Virus virions (viral particles) shows round capsids—protein-encased genetic material—loosely surrounded by the membrane envelope. Credit: DOI: 10.1371/journal.pbio.0030430.g001

The Epstein-Barr virus can cause a spectrum of diseases, including a range of cancers. Emerging data now show that inhibition of a specific metabolic pathway in infected cells can diminish latent infection and therefore the risk of downstream disease, as reported by researchers from the University of Basel and the University Hospital Basel in the journal Science.

Exactly 60 years ago, pathologist Anthony Epstein and virologist Yvonne Barr announced the discovery of a virus that has carried their names ever since. The Epstein-Barr virus (EBV) made scientific history as the first virus proven to cause cancer in humans. Epstein and Barr isolated the pathogen, which is part of the herpesvirus family, from tumor tissue and demonstrated its cancer-causing potential in subsequent experiments.

Most people are carriers of EBV: 90% of the adult population are infected with the virus, usually experiencing no symptoms and no resulting illness. Around 50% become infected before the age of five, but many people don't catch it until adolescence.

Acute infection with the virus can cause —also known as "kissing disease"—and can put infected individuals out of action for several months. In addition to its cancerogenic properties, the pathogen is also suspected to be involved in the development of autoimmune diseases such as multiple sclerosis.

As yet, no drug or approved vaccination can specifically thwart EBV within the body. Now, a research group from the University of Basel and the University Hospital Basel has reported a promising starting point for putting the brakes on EBV.

EBV hijacks the metabolism of infected cells

Researchers led by Professor Christoph Hess have deciphered how the infected with EBV—the so-called B cells—are reprogrammed. Known as "transformation," this process is necessary for the infection to become chronic and cause subsequent diseases such as cancer.

Specifically, the team discovered that the virus triggers the to ramp up the production of an enzyme known as IDO1. This ultimately leads to greater energy production by the power plants of infected cells: the mitochondria. In turn, this additional energy is needed for the increased metabolism and the rapid proliferation of B cells reprogrammed by EBV in this way.

Clinically, the researchers focused on a group of patients who had developed EBV-triggered blood cancer following . To prevent a transplanted organ from being rejected, it is necessary to weaken the immune system using medications. This, in turn, makes it easier for EBV to gain the upper hand and cause blood cancer, referred to as post-transplant lymphoma.

In the paper the researchers were able to show that EBV upregulates the enzyme IDO1 already months before post-transplant lymphoma is diagnosed. This finding may help to develop biomarkers for the disease.

Second chance for a failed drug

"Previously, IDO1 inhibitors have been developed in the hope that they could help to treat established cancer—which has unfortunately turned out not to be the case. In other words, there are already clinically tested inhibitors against this enzyme," explains Hess.

Accordingly, this class of drugs might now receive a second chance in applications aimed at dampening EBV infection and thereby tackling EBV-associated diseases. Indeed, in experiments with mice, IDO1 inhibition with these drugs reduced the transformation of B cells and therefore the viral load and the development of lymphoma.

"In transplant patients, it's standard practice to use drugs against various viruses. Until now, there's been nothing specific for preventing or treating Epstein-Barr virus associated disease," says Hess.

More information: Bojana Müller-Durovic et al, A metabolic dependency of EBV can be targeted to hinder B cell transformation, Science (2024). DOI: 10.1126/science.adk4898. www.science.org/doi/10.1126/science.adk4898

Journal information: Science
Citation: Inhibiting a metabolic pathway provides new approach to Epstein-Barr virus and resulting diseases (2024, May 23) retrieved 16 June 2024 from https://medicalxpress.com/news/2024-05-inhibiting-metabolic-pathway-approach-epstein.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Scientists find weak points on Epstein-Barr virus

88 shares

Feedback to editors